

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)
(amounts in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2022	2021	2022	2021
Grant and collaboration revenue	\$ -	\$ 80	\$ 82	\$ 190
Operating expenses:				
Research and development	1,307	833	2,638	1,436
General and administrative	935	733	2,114	1,805
	<u>2,242</u>	<u>1,566</u>	<u>4,752</u>	<u>3,241</u>
Loss from operations	(2,242)	(1,486)	(4,670)	(3,051)
Other income (expense), net	-	172	1	174
Net loss	<u>\$ (2,242)</u>	<u>\$ (1,314)</u>	<u>\$ (4,669)</u>	<u>\$ (2,877)</u>
Loss per common share	<u>\$ (0.18)</u>	<u>\$ (0.21)</u>	<u>\$ (0.47)</u>	<u>\$ (0.49)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	June 30, 2022	Dec. 31, 2021
Assets:		
Cash and cash equivalents	\$ 30,902	\$ 11,424
Other current assets	1,136	205
Total current assets	<u>32,038</u>	<u>11,629</u>
Property and other assets, net	1,203	168
Total assets	<u>\$ 33,241</u>	<u>\$ 11,797</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 5,368	\$ 7,435
Stockholders' equity	27,873	4,362
Total liabilities and stockholders' equity	<u>\$ 33,241</u>	<u>\$ 11,797</u>
Common shares outstanding	16,238,739	6,381,541